How can policymakers incentivize innovators to invest in new treatments for rare diseases? One solution policymakers invoked was enacting the Orphan Drug Act of 1983 which provided a number of benefits–including lower tax rates–for innovators who created drugs to treat rare diseases.
Was it effective? According to a paper by Miller and Lanthier (2016), the answer is yes.
Before 1983 only 10 drugs had been approved to treat a rare disease, but as of November 2015 over 450 additional new orphan indications (both new drugs and secondary indications for previously approved drugs) had been approved.
This clearly is a large increase. The question is, were these simply “me too” drugs or do these drugs represent significant advances in care.
Beyond Analytics: How Sellers Dorsey is Hard-Coding Value into Medicaid Policy [Video]
How to turn analytics into actual policy outcomes.
Over 50 percent of the drugs were first in class, and 78 percent received a priority review. Drugs approved as either therapeutic or supportive therapies for rare cancers represented the highest proportion of these drugs (35 percent).
Part of the increase here was due to thee identification of genomic subgroups in oncology. Further, this study does not evaluate whether the government funds invested in the Orphan Drug Act were worth the cost. Nevertheless, it is clear that this piece of legislation did incentivize innovators to invest more R&D funds in rare diseases.
Photo: Flickr
Jason Shafrin is a healthcare economist, using quantitative analysis to improve the quality and efficiency of the American health care system. Dr. Shafrin is currently an Economist with Precision Heath Economics and where he uses his interdisciplinary skills in economics, health services research, and health policy to improve the quality and efficiency of the healthcare system. Dr. Shafrin is an expert in value-based purchasing methods, quality of care measures, discrete choice experiments, health insurance claims data analysis, and digital medicine. After receiving a PhD in Economics from the University of California-San Diego, Dr. Shafrin worked at Acumen, LLC helping Medicare implement a variety of the provisions of the Affordable Care Act (a.k.a Obamacare).
The Power Behind Enterprise EHR Software for Large Healthcare Systems
Enterprise EHR boosts scalability, interoperability, and governance for large healthcare systems.
This post appears through the MedCity Influencers program. Anyone can publish their perspective on business and innovation in healthcare on MedCity News through MedCity Influencers. Click here to find out how.